Both were administered at baseline, during exercise, immediately post, and after a 10-min delay.
Outcome Measures: Self-report questionnaires were administered at baseline and 3 and 12 weeks after randomization.
Diagnostic interviews and questionnaires were administered at baseline, post-treatment and 3 months follow-up.
Surveys that included health status assessments were administered at baseline and at 6 and 12 months after intervention.
Following randomization, the interventions were administered at baseline, with booster sessions at 1, 3, and 6 months.
The STarT Back Tool and its reference standard questionnaires (disability, catastrophizing, fear, and depression) were administered at baseline and 4 months later.
Colour vision tests (Ishihara, Farnsworth Munsell D-15, Farnsworth Lantern) were administered at baseline, lens dispensing, and after a 2-week lens-wearing trial during which subjective responses were recorded daily using visual analogue scales.
Neuropsychological tests and the 31-item Quality of Life in Epilepsy (QOLIE-31) inventory were administered at baseline, at the end of the short-term phase, and at the end of the long-term phase.
Two types of health-related quality-of-life questionnaires were administered at baseline and after OLT: generic (Medical Outcomes Study Short Form 36) and liver specific (Chronic Liver Disease Questionnaire).
[22] Each of the four instruments were administered at baseline (i.e., either within seven days prior to the clinic visit of a new upper extremity condition or on the day of the first clinic visit) and at each follow-up visit patients attended.
The following measures were administered at baseline, at 8 and 16 weeks, and at 6th- and 12th-month follow-ups: Eating Disorders Inventory-2 (EDI-2), Hamilton Depression Rating Scale (HDRS), Beck Depression Inventory (BDI), and the Mutual Psychological Development Questionnaire MPDQQ).
